Vyepti works by intercepting a protein called CGRP before it can trigger migraine attacks. CGRP (calcitonin gene-related peptide) is a signaling molecule that spikes during migraines, causing blood vessels in the brain to dilate and pain pathways to fire. Vyepti is a lab-made antibody delivered by IV infusion that grabs onto CGRP and physically blocks it from reaching its receptor, essentially disarming a key trigger in the migraine chain.
How Vyepti Blocks CGRP
CGRP is a small protein your body naturally produces. In people with migraine, CGRP levels surge during attacks and play a central role in the throbbing pain, light sensitivity, and nausea that follow. The protein works by docking onto a receptor on nerve and blood vessel cells, setting off inflammation and pain signaling.
Vyepti’s active ingredient, eptinezumab, is an antibody designed to latch onto CGRP itself, not the receptor. Structural studies show that the antibody forms a deep, narrow pocket between its two protein chains, and the tail end of the CGRP molecule fits snugly inside. Once bound, the antibody undergoes a small physical shift of about 1.4 to 2.0 angstroms in its binding loops, creating what researchers describe as a “latch-and-lock” mechanism that prevents the CGRP from slipping free. The section of CGRP that Vyepti grabs is the exact same region that normally attaches to the CGRP receptor. With that region already occupied, the protein simply cannot activate the receptor, and the downstream cascade of pain signaling never starts.
This approach differs from some other migraine treatments that block the receptor side of the equation. Vyepti neutralizes the messenger itself, sweeping it out of circulation before it ever reaches its target.
Why IV Delivery Matters
Vyepti is the only CGRP-targeting migraine preventive given intravenously. Other drugs in the same class are self-injected under the skin (subcutaneously), which means the medication absorbs gradually through tissue. An IV infusion delivers the full dose directly into the bloodstream over roughly 30 minutes, so Vyepti reaches its peak concentration in the blood by the time the infusion ends.
This matters for speed. Because the drug doesn’t need hours or days to absorb through tissue, it begins neutralizing CGRP almost immediately. In a clinical trial studying eptinezumab given during an active migraine attack, 17.2% of patients achieved sustained headache freedom from 2 hours through 24 hours, compared to 5.8% on placebo. While Vyepti is approved for prevention rather than acute treatment, this data illustrates how quickly the drug reaches effective levels.
Once in the bloodstream, Vyepti has a long half-life of about 27 days, meaning half the drug is still circulating nearly a month after infusion. This is why dosing is spaced every three months: a single infusion provides sustained CGRP suppression for the full interval between treatments.
Dosing and What to Expect
The standard dose is 100 mg given as an IV infusion every three months. Some patients benefit from a higher 300 mg dose on the same schedule. You’ll receive the infusion at a healthcare facility, and the process takes about 30 minutes. After that, there’s no daily pill or monthly self-injection to manage at home until your next quarterly appointment.
This schedule can be appealing if you prefer fewer treatment touchpoints or have trouble remembering daily or monthly medications. The tradeoff is that each dose requires a visit to a clinic or infusion center.
How Well It Reduces Migraine Days
Vyepti’s effectiveness has been tested in both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more). The results from the PROMISE-2 trial, which focused on chronic migraine, are particularly striking. Over 12 weeks, patients on the 100 mg dose experienced an average reduction of 7.7 monthly migraine days, while the 300 mg group saw a reduction of 8.2 days. The placebo group dropped by 5.6 days. Both doses were statistically significant compared to placebo.
For someone with chronic migraine averaging 16 or more migraine days a month, cutting roughly 8 of those days represents a meaningful change in quality of life. Vyepti is FDA-approved for the preventive treatment of migraine in adults, covering both episodic and chronic forms of the condition.
Side Effects
Vyepti is generally well tolerated. The most common side effect in clinical trials was nasopharyngitis, essentially a stuffy or sore throat, occurring in about 14% of patients in the long-term PREVAIL study. This is comparable to what you might expect from a mild seasonal cold.
Hypersensitivity reactions are the more notable risk. In the PREVAIL trial, about 4% of patients experienced some form of allergic-type reaction. In another large trial (DELIVER), hypersensitivity or anaphylaxis occurred in 2% of patients on the 100 mg dose and 3% on the 300 mg dose, rates that were close to placebo in the lower-dose group. Because the drug is given by IV in a medical setting, staff can monitor you during and shortly after the infusion and respond quickly if a reaction occurs.
Serious allergic reactions are rare but possible, which is one reason Vyepti is administered in a clinical environment rather than at home.
How Vyepti Compares to Other CGRP Treatments
Several other migraine preventives target the CGRP pathway, but they differ in how they’re delivered and how they work. Some block the CGRP receptor rather than the protein itself. Vyepti targets the CGRP molecule directly, binding the portion that would otherwise activate the receptor.
The practical differences come down to route and frequency. Self-injectable options are given monthly or quarterly at home using a prefilled device. Vyepti requires a clinic visit every three months but eliminates the need for self-injection. Its IV delivery also means it reaches full blood levels faster than subcutaneous alternatives, which may matter for patients who want rapid onset of preventive effect. If you’re switching from a daily oral preventive or a monthly injectable and want fewer medication-related tasks, the quarterly infusion model may be a better fit. If clinic visits are inconvenient, a home-based option might make more sense. The overall effectiveness across the CGRP drug class is broadly similar, so the choice often comes down to practical preferences and insurance coverage.